Azasite

Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.
Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.
Yahoo/Reuters
Merck
pink eye
Inspire
Azasite
Flag link:
Akorn Acquires U.S. Rights to Trio of Merck Eye Treatments
Akorn Acquires U.S. Rights to Trio of Merck Eye Treatments
Motley Fool
Akorn
Merck
Azasite
Cosopt
Cosopt PF
Flag link:
Merck, Pfizer Sue Mylan to Block Proposed Copy of AzaSite
Merck, Pfizer Sue Mylan to Block Proposed Copy of AzaSite
Bloomberg
Pfizer
Merck
Mylan
Azasite
generics
Flag link:
2 Risks Facing Merck Today
2 Risks Facing Merck Today
Motley Fool
Merck
Vioxx
Azasite
Cancidas
Nasonex
Nexium
Noxafil
Vytorin
Zetia
Emend
generics
Flag link:
Merck, InSite Vision amend payment terms of AzaSite license agreement
Merck, InSite Vision amend payment terms of AzaSite license agreement
Yahoo/Fly on the Wall
Merck
InSite Vision
Azasite
Flag link:
Justice subpoenas Merck on drug marketing
Justice subpoenas Merck on drug marketing
Fierce Pharma
Merck
subpoena
Integrilin
Avelox
Azasite
Flag link:
Inspire's Pink Eye Drug AzaSite Draws Generic Challenge
Inspire's Pink Eye Drug AzaSite Draws Generic Challenge
Motley Fool
Inspire
generics
Azasite
Merck
pink eye
Flag link:
Inspire Pharmaceuticals' eye drug Azasite fails to meet key goals in midstage studies
Inspire Pharmaceuticals' eye drug Azasite fails to meet key goals in midstage studies
Yahoo/AP
Inspire
Azasite
Flag link:
Inspire posts smaller loss as Azasite sales rise
Inspire posts smaller loss as Azasite sales rise
Yahoo/AP
Inspire
earnings
Azasite
Flag link: